ClinicalTrials.gg

Program

Human Dopaminergic Progenitor Cells

Its studies are mostly in Parkinson Disease · Multiple System Atrophy · Parkinsonian Disorders, led by iRegene Therapeutics.

Furthest: phase 2, since Nov 24, 20235 company-led studies, 5 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
iRegene Therapeutics55 open or runningphase 2since Nov 24, 2023Nov 24, 2023Dec 2026phase 2 · NCT07028632

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 24, 2023First study: phase 2 study in Parkinson DiseaseFirst studyNCT06167681 · 40 planned · China
  2. Sep 14, 2024Phase 1 study in Parkinsonian DisordersNCT06608355 · 6 planned · China
  3. Jun 11, 2025Phase 2 study in Parkinson DiseaseNCT07028632 · 30 planned · China
  4. Jul 28, 2025Phase 2 study in Parkinson DiseaseNCT07102342 · 5 planned · United States
  5. Nov 26, 2025Phase 1 study in Multiple System Atrophy - Parkinsonian Subtype (MSA-P)NCT07289477 · 9 planned · China

Ahead

  1. Dec 2026Primary completion: phase 2 study in Parkinson DiseaseNCT07028632
  2. Sep 2027Primary completion: phase 2 study in Parkinson DiseaseNCT07102342
  3. Oct 2027Primary completion: phase 1 study in Multiple System Atrophy - Parkinsonian Subtype (MSA-P)NCT07289477

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07289477Multiple System Atrophy - Parkinsonian Subtype (MSA-P) · China1RecruitingOct 20279
NCT07102342Parkinson Disease · United States2RecruitingSep 20275
NCT07028632Parkinson Disease · China2Not yet recruitingDec 202630
NCT06608355Parkinsonian Disorders · China1RecruitingApr 20266
NCT06167681Parkinson Disease · China2RecruitingDec 202540

How it is read

Names in the registry

  • “Human Dopaminergic Progenitor Cells”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.